Correlation Analysis Of BRCA1 Or BRCA2 Gene Status And Clinicopathological Features In Patients With Epithelial Ovarian Cancer

Objective:This study was performed to investigate the germline BRCA1/2 gene cases in epithelial ovarian cancer,and its relationship with clinicopathological characteristics and prognosis.so as to provide a new idea for the treatment of epithelial ovarian cancer patients.Methods:Epithelial patients who were treated in the Department of Gynecologic Oncology,The First Affiliated Hospital of Bengbu Medical College from December 1,2017 to October 31,2021 and were tested for the germline breast cancer susceptibility gene(BRCA1/2)were selected as the research objects.According to the results of gene detection,they were divided into g BRCA1/2m(+)group and g BRCA1/2m(-)group.The mutation of BRCA1/2 gene in enrolled patients was statistically analyzed,and the clinicopathologic characteristics of initial CA125 level,family history,surgical pathological stage,and length of platinum free interval of patients in the two groups were statistically analyzed.Progression-free survival(PFS)of both groups was followed up,Survival analysis was performed by Kaplan-Meier curve,and meaningful prognostic factors were analyzed by Cox univariate and multivariate.Results:1.Of the 96 patients who underwent genetic testing,29(30.2%)were mutant and 67(69.7%)were wild-type.In the BRCA1/2 gene mutation group,there were 26 cases of BRCA1 gene mutation and 3 cases of BRCA2 gene mutation.Among the BRCA1 gene mutation group,the mutation site of c.5470＿5477del8 appeared most frequently.2.Compared with the two groups,the initial CA125 level and FIGO staging in the mutant group were significantly higher than those in the wild group,and the proportion of family history was higher in the mutant group.Ascites positive in the mutant group was higher than that in the wild group,and the platinum free interval was longer,with statistical significance(all P < 0.05).There were no significant differences in initial treatment,tumor reduction satisfaction,recurrence,first-line platinum chemotherapy sensitivity and age in advanced patients(all P > 0.05).3.The PFS of patients in this study were analyzed by Kaplan Meier curve.According to log-rank analysis,the median PFS of patients with BRCA1/2 gene mutation was 49 months,while that of patients with BRCA1/2 gene wild group was 30 months,the difference was statistically significant(P < 0.05).4.Cox univariate analysis showed that satisfactory surgical reduction degree and BRCA1/2 gene status were prognostic factors for epithelial ovarian cancer patients(P< 0.05).Cox multivariate analysis still showed that tumor reduction degree and BRCA1/2 gene status were independent prognostic factors of PFS(P < 0.05).Conclusions:1.In epithelial ovarian cancer patients with BRCA gene mutation,the mutation frequency of BRCA1 gene is higher than that of BRCA2 gene mutation.2.BRCA1/2 gene status is correlated with clinicopathologic features of epithelial ovarian cancer patients.In epithelial ovarian cancer patients,patients in the BRCA1/2gene mutation group had higher initial CA125 level,tended to be younger,were more common in serous cancer,had a higher proportion of family history,and had longer platinum-free interval in relapsed patients.3.BRCA1/2 status was positively correlated with the prognosis of epithelial ovarian cancer patients.In epithelial ovarian cancer patients,the median progression-free survival was longer in the BRCA1/2 mutant group than in the wild group.4.BRCA1/2 gene status and surgical tumor reduction satisfaction are independent favorable prognostic factors for epithelial ovarian cancer patients.5.BRCA1/2 gene status is a sensitive biological indicator for predicting platinum drug sensitivity and prognosis of patients with epithelial ovarian cancer.